Neoplasms

All Conditions

Rare Diseases

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Apatinib

Ifosfamide

Isophosphamide mustard

Pirarubicin

Mechlorethamine

Doxorubicin

Liposomal doxorubicin

Protein Kinase Inhibitors

Enzyme Inhibitors

Antineoplastic Agents, Alkylating

Alkylating Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.

Apatinib 500mg, orally, once a day. One cycle every 4 weeks.

Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.

Apatinib Mesylate, Pirarubicin, Ifosfamide

Apatinib Mesylate

Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks

Pirarubicin, Ifosfamide

Jilong Yang, M.D., Ph.D

Jilong Yang, M.D., Ph.D.

To observe the efficacy of apatinib combined with AI regimen chemotherapy compared with AI regimen chemotherapy and single-agent apatinib in patients with unresectable soft tissue sarcoma. The main observations were progression-free survival (PFS) and progression-free control rate (PFR), followed by objective response rates (ORR, CR+PR), disease control rate (DCR, CR+PR+SD), and overall survival ( OS).

To observe the safety of apatinib combined with AI chemotherapy.

Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma

Single-center, Open, Non-randomized, Phase II Prospective Study of Apatinib Combined With Chemotherapy in the Treatment of Unresectable Soft Tissue Sarcoma

PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.

Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1（RECIST1.1）

ORR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments.

OS is defined as the length of time from random assignment to death or to last contact.

Tianjin Medical University Cancer Institute and Hospital

Antibodies

Immunoglobulins

Camrelizumab intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.

Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.

Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.

Camrelizumab,

Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.

To observe the effectiveness of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of unresectable sarcoma patients with chemotherapy failure. The main observations were progression-free survival (PFS) and progression-free control rate (PFR), followed by objective response rate (ORR) (CR+PR), disease control rate (DCR) (CR+PR+SD), and overall survival (OS).

To observe the safety of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of sarcoma

Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma

Anti-PD-1 Antibody SHR-1210 (Camrelizumab) Combined With Apatinib Mesylate in the Treatment of Unresectable Sarcoma With Chemotherapy Failure: an Open, Non-randomized Phase II Clinical Study

nvestigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1（RECIST1.1）

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma	NCT04126811	Soft Tissue Sar...	Apatinib Mesyla... Apatinib Mesyla... Pirarubicin, If...	14 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma	NCT04126993	Sarcoma	Camrelizumab, Apatinib	14 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital

Spots Global Cancer Trial Database for jilong yang

Every month we try and update this database with for jilong yang cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for jilong yang

Every month we try and update this database with for jilong yang cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for jilong yang cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.